Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816725/37000/en/Organovo-Presents-FXR314-3D-Human-Tissue-Model-Findings-That-Show-Improved-Epithelial-Barrier-Function-and-Fibrosis-Reduction-at-Crohn-s-and-Colitis-Congress.html

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the Crohn’s and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada.

Read more at globenewswire.com

Related news for (ONVO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.